Immunotherapy for squamous cell carcinoma of the head and neck
- 8 August 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 50 (10), 1089-1096
- https://doi.org/10.1093/jjco/hyaa139
Abstract
Squamous cell carcinoma of the head and neck is characterized by an immunosuppressive environment and evades immune responses through multiple resistance mechanisms. A breakthrough in cancer immunotherapy employing immune checkpoint inhibitors has evolved into a number of clinical trials with antibodies against programmed cell death 1 (PD-1), its ligand PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for patients with squamous cell carcinoma of the head and neck. CheckMate141 and KEYNOTE-048 were practice-changing randomized phase 3 trials for patients with platinum-refractory and platinum-sensitive recurrent or metastatic squamous cell carcinoma of the head and neck, respectively. Furthermore, many combination therapies using anti-CTLA-4 inhibitors, tyrosine kinase inhibitors and immune accelerators are currently under investigation. Thus, the treatment strategy of recurrent or metastatic squamous cell carcinoma of the head and neck is becoming more heterogeneous and complicated in the new era of individualized medicine. Ongoing trials are investigating immunotherapeutic approaches in the curative setting for locoregionally advanced disease. This review article summarizes knowledge of the role of the immune system in the development and progression of squamous cell carcinoma of the head and neck, and provides a comprehensive overview on the development of immunotherapeutic approaches in both recurrent/metastatic and locoregionally advanced diseases.Keywords
This publication has 55 references indexed in Scilit:
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancersNature, 2016
- Combination cancer immunotherapies tailored to the tumour microenvironmentNature Reviews Clinical Oncology, 2015
- Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV SubtypesClinical Cancer Research, 2015
- Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell CarcinomasClinical Cancer Research, 2015
- Comprehensive genomic characterization of head and neck squamous cell carcinomasNature, 2015
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector FunctionCancer Cell, 2014
- The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neckOral Oncology, 2014
- Epstein-Barr Virus as a Paradigm in Nasopharyngeal Cancer: From Lab to ClinicAsco Educational Book, 2014
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infectionProceedings of the National Academy of Sciences, 2010